Strategic Funding Log10 recently secured seed funding of 7.2M led by TQ Ventures and Quiet Capital, signaling strong investor confidence and potential for scaling sales efforts targeting venture-backed pharma and CRO clients.

Regulatory Acceleration Everest automates regulatory-ready medical writing across clinical, regulatory, and submissions, presenting a clear value prop to CROs, consultancies, and life sciences teams seeking faster documentation and reduced headcount.

Enterprise-Ready Tech With a specialized AI foundation focused on accuracy and auditability, Log10 leverages a reputable tech stack (OpenAI, Claude, GCP, TensorFlow) that resonates with enterprise buyers prioritizing compliance and reliability.

Mid-Market Focus Headcount and revenue indicators place Log10 in a growth-oriented segment ideal for expanding through mid-sized pharma services firms, biotechs, and regulatory consultancies seeking scalable writing platforms.

Growth Lever A combined revenue range of 25–50M and seed funding runway enables targeted outreach to finance, partnerships, and solutions procurement roles within prospective clients looking to modernize clinical documentation workflows.